- Home
- HSPO vs MAIA Comparison
HSPO vs MAIA Comparison
Compare HSPO & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HSPO
- MAIA
- Stock Information
- Founded
- HSPO 2014
- MAIA 2018
- Country
- HSPO United States
- MAIA United States
- Employees
- HSPO N/A
- MAIA N/A
- Industry
- HSPO Blank Checks
- MAIA Biotechnology: Pharmaceutical Preparations
- Sector
- HSPO Finance
- MAIA Health Care
- Exchange
- HSPO Nasdaq
- MAIA Nasdaq
- Market Cap
- HSPO 87.7M
- MAIA 62.4M
- IPO Year
- HSPO 2022
- MAIA 2022
- Fundamental
- Price
- HSPO $11.25
- MAIA $2.82
- Analyst Decision
- HSPO
- MAIA
- Analyst Count
- HSPO 0
- MAIA 0
- Target Price
- HSPO N/A
- MAIA N/A
- AVG Volume (30 Days)
- HSPO 27.4K
- MAIA 60.0K
- Earning Date
- HSPO 01-01-0001
- MAIA 11-05-2024
- Dividend Yield
- HSPO N/A
- MAIA N/A
- EPS Growth
- HSPO N/A
- MAIA N/A
- EPS
- HSPO 0.33
- MAIA N/A
- Revenue
- HSPO N/A
- MAIA N/A
- Revenue This Year
- HSPO N/A
- MAIA N/A
- Revenue Next Year
- HSPO N/A
- MAIA N/A
- P/E Ratio
- HSPO $34.26
- MAIA N/A
- Revenue Growth
- HSPO N/A
- MAIA N/A
- 52 Week Low
- HSPO $10.60
- MAIA $0.82
- 52 Week High
- HSPO $11.25
- MAIA $5.99
- Technical
- Relative Strength Index (RSI)
- HSPO 69.42
- MAIA 50.98
- Support Level
- HSPO $11.17
- MAIA $2.36
- Resistance Level
- HSPO $11.25
- MAIA $2.72
- Average True Range (ATR)
- HSPO 0.00
- MAIA 0.22
- MACD
- HSPO 0.00
- MAIA 0.02
- Stochastic Oscillator
- HSPO 100.00
- MAIA 72.28
About HSPO Horizon Space Acquisition I Corp.
Horizon Space Acquisition I Corp is a blank check company.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company. The company develops targeted immunotherapies for cancer. The company is an immune-oncology company, focused on the development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. The company's program is THIO, a potential cancer telomere-targeting agent in clinical development for the treatment of telomerase-positive cancer cells.